Vitasora Health (VHL) H2 2025 earnings summary

Executive summary

• Completed a major rebrand and transformation, expanding from a respiratory-focused company to a diversified, technology-enabled chronic care management provider in the U.S. market.

• Acquired Orb Health, accelerating U.S. market penetration and expanding service offerings, with rapid integration and operational efficiencies.

• Ended FY25 with 20,863 active patient programs and $3 million in revenue, supported by a pipeline covering 1.2 million lives.

• Aligned with U.S. healthcare reform and value-based care mandates, leveraging AI and automation for scalable growth.

• Secured $11 million in post-year-end institutional commitments, funding operations through to cash flow breakeven in H1 CY2026.

Financial highlights

• FY25 revenue was $3.7 million, including $3.1 million in operating revenue, with a record $2.1 million in H2 driven by Orb Health and organic growth.

• Net loss after tax was $10.1 million (2024: $7.1 million); operating cash outflow was $9.2 million (2024: $6.6 million).

• Service mix: 48% Chronic Care Management, 26% Remote Patient Monitoring, 14% Principal Care Management, 9% Transitional Care Management.

• Realized merger synergies post-Orb Health acquisition, reducing monthly losses from US$453K to US$305K.

• Cash on hand at year end was $394K; inventories totaled $2.88 million.

Outlook and guidance

• Projected significant revenue growth in FY26, with revenue growth modeled at 45% per annum for years 2-5.

• Operations funded through to cash flow breakeven in H1 CY2026, supported by recent capital raises.

• Focus on securing large-scale, recurring contracts and expanding in high-value U.S. markets.